AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0079
Drug name and formulations:	Trelegy Ellipta® (fluticasone furoate, vilanterol trifenatate, umeclidinium bromide)

Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	Adverse effects comparable to inhalers containing constituent ingredients. Pneumonia reported in small number of patients.
Clinical effectiveness	*Established licensed product*	Evidence of reduction in COPD exacerbations, demonstrating superiority to inhalers containing constituent ingredients
Strength of evidence		Robust
Cost effectiveness or resource impact	*£*	Cost effective compared to using two separate inhalers containing constituent ingredients
Place of therapy relative to available treatments	*1/2nd tier*	In line with COPD guidance
National guidance and priorities	*NICE, MTRAC*	Not reviewed by MTRAC
Local health priorities	*CCG views*	CCGs supportive
Equity of access	*Equality assessment*	N/A
Stakeholder views	*Define wider groups to be engaged*	N/A
Implementation requirements	*Requires, RICAD ESCA etc.*	In line with COPD guidance

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	GREEN
Implementation requirements:	
Implementation monitoring:	